Tegsedi (inotersen, Akcea™ Therapeutics)
Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Dosage: 284 mg adminstered by subcutaneous injection 1x weekly
Contraindications
2 Clarke Drive
Cranbury, NJ 08512